Connect with us

Biotechnology

3 Biotech Stocks To Watch After Big News This Month

Joe Samuel

Published

on

If there is one sector that has grown immensely strong over the past decade and a half, then it’s biotech. These biotech stocks and underlying companies have come up with highly innovative solutions to a range of diseases. Furthermore, it has been through the use of technology and knowledge of pharmaceuticals, which has added to the innovation.

As a consequence, the sector has grown considerably and a lot of investor capital has flooded into the sector. However, in order to make a return on investment, an investor needs to keep a close eye on the market and then make his investments after he has made a list of the biotech stocks to invest in. On that note, here is a look at 3 biotechnology stocks that proved to be winners recently.

Biotech Stock #1:
PharmaCyte Biotech

PharmaCyte Biotech (PMCB Stock Report) recently announced the appointment of David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Judd also works at Grand Island Biotechnology Company and is involved in research, process development and cGMP production of biotechnology and cell therapy processes. This could make a perfect fit for him at PharmaCyte.

biotech stocks to buy

If you’re looking at PharmaCyte Biotech at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company. At this point, PharmaCyte is focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box.

Here’s why an open IND is key to PharmaCyte (PMCB) realizing a number of benefits that include:

  • Beginning the formal arrangements required to conduct its clinical trial in LAPC.
  • Working towards the major milestone of enrolling the first patient in its clinical trial.
  • Publishing that the technology behind its LAPC treatment has passed the incredibly difficult FDA screening process and met all of the FDA’s regulatory requirements.
  • Building global exposure of PharmaCyte’s Cell-in-a-Box® technology.
  • Paving the way for the development of treatments for multiple diseases including diabetes and a host of solid tumors. 

Biotech Stock #2:
Provention Bio

The next one to look at is Provention Bio Inc (PRVB Stock Report). The biotech stock has been on a hugely impressive rally this year so far. The biotech stock price has surged by as much as 550% in 2019. Why? The big trigger was the results of a National Institute of Health study into the PRV-031 medicine that was published last month.

The study found significant insight in the company’s PRV-031 medicine. If it’s administered over the course of two weeks, the onset of Type 1 diabetes can be delayed by as long as two years. This was found in patients who are at high risk.

PRVB biotech stock price

Additionally, Provention had started a Phase 3 clinical study of the PRV-031 product back in April. That proved to be an important trigger as well. Enrollment for the Phase 2 study of its Crohn’s disease medicine PRV-6527 has also been concluded.

Biotech Stock #3:
ArQule

The other biotech stock to watch had an excellent run in June. The clinical-stage pharmaceutical firm ArQule, Inc. (ARQL Stock Report) stock jumped as much as 53% over the course of last month.

best-biotech-stocks-ARQL-Arqule-stock

This was due to highly promising data from two clinical trials of its product ARQ 531. The trials showed that its medicine had an effect on cancer variants that affect the white blood cells. The biotech stock also managed to raise substantial capital through a private offering. Moreover, the stock is up 280% since the beginning of this year.

biotech stocks to watch
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading
Click to comment

Biotechnology

PharmaCyte Biotech to Hold Special Shareholder Meeting

A. Lawrence

Published

on

biotechnology stock price

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–

PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019. The shareholder meeting, not to be confused with a shareholder conference call, will be held at the Courtyard by Marriott in Irvine, California, and will begin at 11:00 a.m. Pacific Daylight Time.

During the meeting there will be an update on PharmaCyte’s current research-related projects followed by a question and answer session regarding the update. The meeting will then turn to management matters, such as: (i) amending PharmaCyte’s Articles of Incorporation to provide the Board of Directors (“Board”) the power to designate the rights and preferences of PharmaCyte’s preferred stock; (ii) election of six directors as nominated by the Board’s Nominating Committee and approved by the Board, each to serve a one-year term; (iii) ratification of the appointment of Armanino LLP as PharmaCyte’s independent registered public accounting firm for the fiscal year ending April 30, 2020 and (iv) to consider and act upon any other business as may properly come before the Special Shareholder Meeting.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “This shareholder meeting will be the first during my tenure as CEO. Since the new management team took over in 2014, we have faced untold challenges and hurdles virtually every day. We have persevered. We believe we’re on the brink of a new dawn for the company as we work collaboratively with so many stellar professional colleagues to showcase the unique Cell-in-a-Box® technology in which so many have worked so diligently over the past several years. We feel that it is important to realize our full potential while, at the same time, bringing value to and protecting our shareholders who have stood by us for so long.

“We look forward to meeting many of our long-standing and new shareholders who can attend and in implementing the steps that will enable us to succeed on numerous fronts.”

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005275/en/

Contact:
Dr. Gerald W. Crabtree
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Biotechnology

Stock Price Morning Update For Thursday, August 15, 2019

A. Lawrence

Published

on

stock market news today

3 Biotech Stocks In Focus As Cancer Treatment Heats Up

Over the years, biotech stocks have been able to create a lot of wealth for investors and hence, it is no surprise that there are investors who are actively in search of the next big thing in cancer-related stocks. Here is a look at two such stocks which should be on investors’ watch lists.

Click To Read More


Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market

Technology has evolved over the years, and so have online websites and apps. Growing food delivery apps are the newest trend, expanding revenue generation in the food-service industry by 22% or more. And this new trend has created an even greater opportunity beyond food delivery alone!

SPECIAL REPORT


Walmart (WMT) Stock Price Jumps On Latest Earnings Beat

Shares of Walmart are screaming during premarket. See what results are helping build the buzz around this retail stock

Click Here For More

Continue Reading

Biotechnology

3 Biotech Stocks In Focus As Cancer Treatment Heats Up

A. Lawrence

Published

on

biotech stock to buy 2019

For as long as anyone can remember, biotech stocks and pharmaceutical companies get lots of attention. Many are involved in cancer research have always generated a lot of interest for investors. The reason is that any kind of breakthrough in cancer treatments can lead to enormous profits for the company. That is what investors look for.

Over the years, such stocks have been able to create a lot of wealth for investors and hence, it is no surprise that there are investors who are actively in search of the next big thing in cancer-related stocks. Here is a look at two such stocks which should be on investors’ watch lists.

Biotech Stock To Watch#1: PharmaCyte Biotech (PMCB)

If you’re looking at PharmaCyte Biotech (PMCB Stock Report) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to pharmaceutical stocks or a seasoned vet, you should understand how important milestones like this are for a company.

Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Just to give you an idea, pancreatic cancer, in general, has the highest death rate of all major cancers. Only 9% of people with this cancer will survive more than five years [1].

This isn’t “just another cancer company.” PharmaCyte (PMCB) has developed a technology that could completely change the way cell therapies are conducted! Right now, the company isn’t just focused on cancer, they’ve also begun to apply Cell In A Box ® to other diseases like Diabetes.

Read The Latest On This Development: PharmaCyte Biotech (PMCB) and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes

PharmaCyte (PMCB) has entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes with the potential to express higher levels of insulin. PharmaCyte has obtained the exclusive worldwide license rights from UTS to use these cells to develop a therapy for Type 1 and insulin-dependent Type 2 diabetes.

Deciphera Pharmaceuticals (DCPH) Has Biotech Stock Investors Watching Closely

The next on this list of biotech stocks to watch: Deciphera Pharmaceuticals Inc (DCPH Stock Report). This stock has been in the middle of a hugely impressive rally this week. The biotech company has been working on a stomach cancer medicine of its own. In a new development, it emerged that the medicine in question proved to be beneficial to patients.

DCPH stock

It was further pointed out that the patients in question had been treated with all other medicines. But none of those proved to be effective enough. This announcement was made on Tuesday and soon enough DCPH stock started to climb. The stock rose by as much as 80% and remains one of the hottest cancer-related stocks in the market at the moment.

High Priced Biotech Stock To Watch: Amgen (AMGN)

The other cancer-related stock that has been in the news this month is Amgen, Inc. (AMGN Stock Report). The company announced a major breakthrough. Amgen managed to produce a medicine named AMG 510. It helps target KRAS mutated cancer. It goes without saying that it is a breakthrough that took decades to delivery. But it is believed that it is a product that could eventually change the face of the company as a whole.

>Read More< The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company

The company also won its case against Novartis, this month. Amgen’s opponent, Sandoz (a unit of Novartis) didn’t meet its burden to claim several patent infringements were invalid.

“We are pleased with today’s decision recognizing the validity of these patents. Protecting intellectual property is critical to incentivize innovation and the large investments in research and development that are required to bring new medicines to patients and fully develop their therapeutic potential for patients.”

Robert A. Bradway, chairman and chief executive officer at Amgen
biotech stock to watch 2019
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

End Notes:

[1]http://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts/

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com